The LA CaTS Center was recently awarded two new NIH Administrative Supplement Grants focused on women's health and effects of weight loss with GLP-1 receptor agonist drugs. The grants are for a one-year period. Congratulations to the project leads for their significant work on these crucial studies addressing chronic diseases that affect our state. 

Click on the dropdowns below for more information. 

Yilin Yoshida

This project aims to uncover why women with young-onset type 2 diabetes (T2D) face a higher risk of heart failure (HF) as they age. With the rising rates of T2D, especially among women, it's crucial to explore how early life factors and lifestyle choices influence heart health over time. The study focuses on a diverse group of 3,499 individuals tracked over 30 years. By examining metabolic risk factors, physical activity levels, and heart health indicators, researchers will analyze how these elements contribute to the development of heart failure. One key area of interest is how physical activity might help mitigate the increased risk women face compared to men. By understanding these dynamics, the project seeks to identify modifiable risk factors that could lead to targeted interventions. Ultimately, the goal is to improve heart health outcomes for women with T2D and develop strategies that address their unique risks, paving the way for better prevention and treatment of heart failure.

TEAM Science Leads

The Louisiana Clinical and Translational Science (LA CaTS) Center, in collaboration with the Northern New England Clinical and Translational Research Network (NNE-CTR), is embarking on a vital study to assess the effects of the weight loss drug tirzepatide on muscle and bone health, particularly in under-represented populations. As the use of this medication—originally developed for type 2 diabetes—grows, understanding its broader health implications becomes crucial.

This project aims to address health disparities by focusing on groups often excluded from clinical trials, such as non-Hispanic Black and rural White individuals, who experience higher rates of obesity and related health issues.

While tirzepatide promotes rapid weight loss, concerns have emerged regarding potential side effects, including the loss of skeletal muscle and bone density. Healthy muscle is essential for metabolic function and maintaining bone strength is critical for preventing fractures.

The research will harness the combined expertise of the Pennington Biomedical Research Center and the MaineHealth Institute for Research Skeletal Laboratories. By studying the impacts of tirzepatide on muscle and bone health over time, the project aims to fill significant knowledge gaps and inform safer treatment strategies for vulnerable populations, ensuring that weight loss therapies enhance health outcomes without compromising musculoskeletal integrity.